Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

The effects of a 5-hydroxytryptamine 1A receptor gene polymorphism on the clinical response to fluvoxamine in depressed patients

Abstract

We investigated the effects of a 5-hydroxytryptamine (5-HT) 1A receptor gene polymorphism on the clinical response to fluvoxamine (FLV) in 65 depressed outpatients who gave written consent to participate in the study. Patients visited every 2 weeks after the first examination until the week 12 end point and were evaluated by the 17-item Hamilton Rating Scale for Depression (HAM-D-17) at each visit. FLV dose was changed in response to their clinical symptoms. The Gly272Asp polymorphism of the 5-HT1A receptor gene was identified by a PCR method. The subjects with the Asp allele had a significantly higher % reduction in the HAM-D-17 score than those with the Gly/Gly genotype at week 2 (P=0.009), week 6 (P=0.036), and week 12 (P=0.031). There was a significant difference in the genotype distribution between the responders and nonresponders. These results suggest that the Gly272Asp polymorphism of the 5-HT1A receptor gene may predict the response to FLV.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Judd LL . Mood disorders in the general population represent an important and worldwide public health problem. Int Clin Psychopharmacol 1995; 10 (Suppl 4): 5–10.

    Article  PubMed  Google Scholar 

  2. National Advisory Mental Health Council. Health care reform for Americans with severe mental illnesses: report of the National Advisory Mental Health Council. Am J Psychiatry 1993; 150: 1447–1465.

  3. Guscott R, Grof P . The clinical meaning of refractory depression: a review for the clinician. Am J Psychiatry 1991; 148: 695–704.

    Article  CAS  PubMed  Google Scholar 

  4. Blier P, de Montigny C . Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994; 15: 220–226.

    Article  CAS  PubMed  Google Scholar 

  5. Blier P, de Montigny C, Chaput Y . Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. J Clin Psychopharmacol 1987; 7 (Suppl): 24S–35S.

    CAS  PubMed  Google Scholar 

  6. Hyttel J . Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 1994; 9 (Suppl 1): 19–26.

    Article  PubMed  Google Scholar 

  7. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 1994; 46: 157–203.

    CAS  PubMed  Google Scholar 

  8. Artigas F, Romero L, de Montigny C, Blier P . Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 1996; 19: 378–383.

    Article  CAS  PubMed  Google Scholar 

  9. Chaput Y, de Montigny C, Blier P . Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: electrophysiological studies in the rat brain. Naunyn-Schmiedeberg's Arch Pharmacol 1986; 333: 342–348.

    Article  CAS  Google Scholar 

  10. Bel N, Artigas F . Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse 1993; 15: 243–245.

    Article  CAS  PubMed  Google Scholar 

  11. Fuller RW . Uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysis. Life Sci 1994; 55: 163–167.

    Article  CAS  PubMed  Google Scholar 

  12. Rutter JJ, Gundlah C, Auerbach SB . Increase in extracellular serotonin produced by uptake inhibitors is enhanced after chronic treatment with fluoxetine. Neurosci Lett 1994; 171: 183–186.

    Article  CAS  PubMed  Google Scholar 

  13. Bordet R, Thomas P, Dupuis B . Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. Reseau de Recherche et d'Experimentation Psychopharmacologique. Am J Psychiatry 1998; 155: 1346–1351.

    Article  CAS  PubMed  Google Scholar 

  14. Perez V, Puiigdemont D, Gilaberte I, Alvarez E, Artigas F . Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors. J Clin Psychopharmacol 2001; 21: 36–45.

    Article  CAS  PubMed  Google Scholar 

  15. Nakhai B, Nielsen DA, Linnoila M, Goldman D . Two naturally occurring amino acid substitutions in the human 5-HT1A receptor: glycine 22 to serine 22 and isoleucine 28 to valine 28. Biochem Biophys Res Commun 1995; 210: 530–536.

    Article  CAS  PubMed  Google Scholar 

  16. Erdmann J, Shimron-Abarbanell D, Cichon S, Albus M, Maier W, Lichtermann D et al. Systematic screening for mutations in the promoter and the coding region of the 5-HT1A gene. Am J Med Genet 1995; 60: 393–399.

    Article  CAS  PubMed  Google Scholar 

  17. Kawanishi Y, Harada S, Tachikawa H, Okubo T, Shiraishi H . Novel mutations in the promoter and coding region of the human 5-HT1A receptor gene and association analysis in schizophrenia. Am J Med Genet 1998; 81: 434–439.

    Article  CAS  PubMed  Google Scholar 

  18. Nishiguchi N, Shirakawa O, Ono H, Nishimura A, Nushida H, Ueno Y et al. Lack of an association between 5-HT1A receptor gene structural polymorphisms and suicide victims. Am J Med Genet 2002; 114: 423–425.

    Article  PubMed  Google Scholar 

  19. Tome MB, Isaac MT, Harte R, Holland C . Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int Clin Psychopharmacol 1997; 12: 81–89.

    Article  CAS  PubMed  Google Scholar 

  20. Perez V, Gilaberte I, Faries D, Alvarez E, Artigas F . Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 1997; 349: 1594–1597.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This research was supported by Grants-in-Aid for Scientific Research (KAKENHI) from the Japan Society for the Promotion of Research (JSPS) (#13670991 and #13671000).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to T Someya.

Additional information

DUALITY OF INTEREST

None declared.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Suzuki, Y., Sawamura, K. & Someya, T. The effects of a 5-hydroxytryptamine 1A receptor gene polymorphism on the clinical response to fluvoxamine in depressed patients. Pharmacogenomics J 4, 283–286 (2004). https://doi.org/10.1038/sj.tpj.6500256

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.tpj.6500256

Keywords

This article is cited by

Search

Quick links